RecruitingNCT06988605
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Sponsor
Galderma R&D
Enrollment
1,000 participants
Start Date
Jul 14, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Eligibility
Min Age: 12 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a new treatment for people with atopic dermatitis. The study is currently recruiting participants at 108 locations. People eligible for this study include aged 12 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(108)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06988605
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
Studies of Skin Microbes in Healthy People and in People With Skin Conditions
NCT006058781 location
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT0639791116 locations
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
NCT065994111 location
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
NCT076458204 locations